Delays in financial reporting, especially for a biotech company like Bluebird Bio Inc, can lead to negative investor sentiment. Such delays might raise questions about the company's internal processes or potential issues that are not yet public. This uncertainty can lead to a decrease in stock price in the short term as investors may perceive the delay as a sign of potential problems within the company.